Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Drug Class Review: Alzheimer's Drugs: Final Report [Internet].

Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T.

Portland (OR): Oregon Health & Science University; 2006 Jun.

2.

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A.

Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. Review.

3.

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C.

Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210. Review.

4.

Treatment of Alzheimer's disease in the long-term-care setting.

Smith DA.

Am J Health Syst Pharm. 2009 May 15;66(10):899-907. doi: 10.2146/ajhp070622. Review.

PMID:
19420308
5.

Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.

Standridge JB.

Clin Ther. 2004 May;26(5):615-30. Review.

PMID:
15220008
6.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

8.

Relative tolerability of Alzheimer's disease treatments.

Alva G, Cummings JL.

Psychiatry (Edgmont). 2008 Nov;5(11):27-36.

9.

A practical algorithm for managing Alzheimer's disease: what, when, and why?

Cummings JL, Isaacson RS, Schmitt FA, Velting DM.

Ann Clin Transl Neurol. 2015 Mar;2(3):307-23. doi: 10.1002/acn3.166. Epub 2015 Jan 23. Review.

10.

Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

Nordberg A, Svensson AL.

Drug Saf. 1998 Dec;19(6):465-80. Review. Erratum in: Drug Saf 1999 Feb;20(2):146.

PMID:
9880090
11.

The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.

Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty JP.

Postgrad Med. 2005 Jan;Spec No:6-22.

PMID:
17203561
12.

Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors.

Shi X, Lin X, Hu R, Sun N, Hao J, Gao C.

Am J Alzheimers Dis Other Demen. 2016 Aug;31(5):405-12. doi: 10.1177/1533317515622283. Epub 2016 Jan 14.

PMID:
26769920
13.

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.

Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L.

J Alzheimers Dis. 2014;41(2):615-31. doi: 10.3233/JAD-132690. Review.

PMID:
24662102
14.

Effective pharmacological management of Alzheimer's disease.

Atri A.

Am J Manag Care. 2011 Nov;17 Suppl 13:S346-55. Review.

15.

Combination therapy for Alzheimer's disease.

Patel L, Grossberg GT.

Drugs Aging. 2011 Jul 1;28(7):539-46. doi: 10.2165/11591860-000000000-00000. Review.

PMID:
21721598
16.
17.
18.

Beyond symptomatic effects: Donepezil's potential for neuroprotection and disease modification in Alzheimer's disease.

Kim SH, Kandiah N, Hsu JL, Suthisisang C, Udommongkol C, Dash A.

Br J Pharmacol. 2017 Sep 13. doi: 10.1111/bph.14030. [Epub ahead of print] Review.

PMID:
28901528
19.

Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.

Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M.

Ann Intern Med. 2008 Mar 4;148(5):379-97. Review.

PMID:
18316756
20.

Pharmacologic treatments of dementia.

Bonner LT, Peskind ER.

Med Clin North Am. 2002 May;86(3):657-74. Review.

PMID:
12171061

Supplemental Content

Support Center